For research use only. Not for therapeutic Use.
RTC13（Cat No.:I012257）is a small molecule inhibitor that selectively targets and inhibits the protein phosphatase 2A (PP2A) regulatory subunit B56, a key component of the PP2A holoenzyme. By modulating PP2A activity, RTC13 is used in research to explore the regulation of various signaling pathways, including those involved in cell cycle control, apoptosis, and tumorigenesis. Its potential therapeutic applications lie in cancer treatment, as inhibiting PP2A could enhance the efficacy of other anticancer therapies. Research is ongoing to evaluate RTC13’s impact on tumor growth and its broader clinical potential.
| CAS Number | 1359825-94-7 |
| Synonyms | (5Z)-2-imino-5-[[5-(2-nitrophenyl)furan-2-yl]methylidene]-1,3-thiazolidin-4-one |
| Molecular Formula | C14H9N3O4S |
| Purity | ≥95% |
